Literature DB >> 8625297

Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma relative to adenoma cell lines.

D J Elder1, A Hague, D J Hicks, C Paraskeva.   

Abstract

Regular aspirin intake may reduce the risk of colorectal cancer by 50%. However, the mechanism of this chemopreventive effect is not known. The effect of the aspirin metabolite salicylate on the growth of human colorectal tumor cell lines was determined. Salicylate showed dose-dependent inhibitory effects on all of the cell lines (IC50, 1.65 +/- 0.36 to 7.38 +/- 1.08 mM), yet carcinoma and in vitro-transformed adenoma cell lines were more sensitive than adenoma cell lines. Salicylate caused all cell lines to accumulate in G0-G1 and induced apoptosis in carcinoma and in vitro-transformed adenoma cell lines but not in all adenoma cell lines. In those adenoma lines that did show salicylate-induced apoptosis, the extent was considerably less than that in the more transformed cell lines. The ability of salicylate to induce cell cycle arrest and apoptosis and, in particular, the increased sensitivity of cells at later stages of neoplastic progression may be mechanistically important in the chemopreventive action of aspirin toward colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8625297

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

1.  Sodium salicylate inhibits proliferation and induces G1 cell cycle arrest in human pancreatic cancer cell lines.

Authors:  R A Perugini; T P McDade; F J Vittimberga; A J Duffy; M P Callery
Journal:  J Gastrointest Surg       Date:  2000 Jan-Feb       Impact factor: 3.452

Review 2.  Colon cancer: polyps, prevention, and politics.

Authors:  G L Eastwood
Journal:  Trans Am Clin Climatol Assoc       Date:  1998

3.  The apoptotic inducible effects of salicylic acid on hepatoma cell line: relationship with nitric oxide signaling.

Authors:  Yahui Liu; Yong Wang; Yue Hu; Shuxiong Ge; Keshi Li; Shuangshuang Wang; Li Li
Journal:  J Cell Commun Signal       Date:  2017-02-09       Impact factor: 5.782

4.  Pharmacological inhibition of protein kinase C activity could induce apoptosis in gastric cancer cells by differential regulation of apoptosis-related genes.

Authors:  G H Zhu; B C Wong; M C Eggo; S T Yuen; K C Lai; S K Lam
Journal:  Dig Dis Sci       Date:  1999-10       Impact factor: 3.199

5.  Long-range epigenetic silencing of chromosome 5q31 protocadherins is involved in early and late stages of colorectal tumorigenesis through modulation of oncogenic pathways.

Authors:  A R Dallosso; B Øster; A Greenhough; K Thorsen; T J Curry; C Owen; A L Hancock; M Szemes; C Paraskeva; M Frank; C L Andersen; K Malik
Journal:  Oncogene       Date:  2012-01-16       Impact factor: 9.867

Review 6.  Role of chemoprophylaxis with either NSAIDs or statins in patients with Barrett's esophagus.

Authors:  Panagiotis Tsibouris; Erasmia Vlachou; Peter Edward Thomas Isaacs
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-02-06

Review 7.  Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis.

Authors:  O C Trifan; T Hla
Journal:  J Cell Mol Med       Date:  2003 Jul-Sep       Impact factor: 5.310

Review 8.  Chemoprevention of colorectal cancer.

Authors:  M Langman; P Boyle
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

9.  The identification of salicylates as normal constituents of serum: a link between diet and health?

Authors:  J R Paterson; C Blacklock; G Campbell; D Wiles; J R Lawrence
Journal:  J Clin Pathol       Date:  1998-07       Impact factor: 3.411

10.  The proapoptotic BH3-only protein Bim is downregulated in a subset of colorectal cancers and is repressed by antiapoptotic COX-2/PGE(2) signalling in colorectal adenoma cells.

Authors:  A Greenhough; C A Wallam; D J Hicks; M Moorghen; A C Williams; C Paraskeva
Journal:  Oncogene       Date:  2010-03-29       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.